Cubist Systematic Strategies’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Cubist Systematic Strategies’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-51,903	Closed	-$524K	–	4767
2022 Q4	$524K	Sell	51,903 -8,632	-14%	-$86.3K	﹤0.01%	2980
2022 Q3	$600K	Sell	60,535 -20	-0%	-$197	﹤0.01%	3026
2022 Q2	$593K	Buy	60,555 +34,896	+136%	+$342K	﹤0.01%	2920
2022 Q1	$250K	Buy	+25,659	New	+$249K	﹤0.01%	2945

Cubist Systematic Strategies's EBAC Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 51,903 shares — an estimated $524K sold.

Cubist Systematic Strategies first reported a position in EBAC in Q1 2022 and held it in 4 quarters. The position peaked at $600K in Q3 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Cubist Systematic Strategies reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 51,903 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $524K.
Cubist Systematic Strategies first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 4 quarters.
Cubist Systematic Strategies's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $600K in Q3 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.